<p>Kodiak Sciences（納斯達克股票代碼：KOD - 獲取免費報告）於週四發佈了季度財報。公司報告本季度每股收益（EPS）為（$0.84），超出市場共識預期的（$0.90）$0.06，Zacks 報道。</p>
<p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<h2>Kodiak Sciences 股票表現</h2>
<p>納斯達克：KOD 週五開盤價為 $3.06。該股票的 50 日簡單移動平均線為 $4.93，200 日簡單移動平均線為 $5.40。Kodiak Sciences 的 52 周最低價為 $2.19，52 周最高價為 $11.60。公司的市值為 $1.6103 億，市盈率為 -0.84，貝塔係數為 2.26。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，傑富瑞金融集團在 12 月 9 日的研究報告中將 Kodiak Sciences 的股票評級從 “持有” 上調至 “買入”，並設定了 $20.00 的目標價。</p>
<p><strong>閲讀我們關於 KOD 的最新股票報告</strong></p>
<h2>Kodiak Sciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Kodiak Sciences Inc 是一家臨牀階段的生物製藥公司，研究、開發和商業化治療視網膜疾病的療法。其主要產品候選藥物是 tarcocimab tedromer（KSI-301），這是一種抗血管內皮生長因子抗體生物聚合物，目前正在進行治療濕性年齡相關性黃斑變性（AMD）的 IIb/III 期臨牀研究，以及用於治療糖尿病性黃斑水腫、因視網膜靜脈阻塞引起的初發性黃斑水腫和非增殖性糖尿病視網膜病變的 III 期臨牀研究。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Kodiak Sciences</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>便士股票激增 70%：買入的一個理由，賣出的五個理由</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>公用事業股票解析 – 如何以及為何投資公用事業</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E"/></p>
<h2>你現在應該投資 $1,000 在 Kodiak Sciences 嗎？</h2>
<p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Kodiak Sciences 並不在名單上。</p>
<p>雖然 Kodiak Sciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Kodiak Sciences（納斯達克代碼：KOD）報告的季度每股收益為（$0.84），超出分析師預期的（$0.87）$0.03。該股票開盤價為$3.06，市值為 1.6103 億美元。傑富瑞金融集團將 Kodiak Sciences 的評級從 “持有” 上調至 “買入”，目標價為$20.00。該公司專注於開發視網膜疾病的治療藥物，其主要產品候選藥物正在進行高級臨牀研究</p>

<p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.</p>
<div class="lb-trans"><p>Kodiak Sciences（納斯達克股票代碼：KOD - 獲取免費報告）於週四發佈了季度財報。公司報告本季度每股收益（EPS）為（$0.84），超出市場共識預期的（$0.90）$0.06，Zacks 報道。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表現</h2>
</div><p>NASDAQ:KOD opened at $3.06 on Friday. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $5.40. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60. The company has a market cap of $161.03 million, a PE ratio of -0.84 and a beta of 2.26.</p>
<div class="lb-trans"><p>納斯達克：KOD 週五開盤價為 $3.06。該股票的 50 日簡單移動平均線為 $4.93，200 日簡單移動平均線為 $5.40。Kodiak Sciences 的 52 周最低價為 $2.19，52 周最高價為 $11.60。公司的市值為 $1.6103 億，市盈率為 -0.84，貝塔係數為 2.26。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $20.00 target price on the stock in a research note on Monday, December 9th.</p>
<div class="lb-trans"><p>另外，傑富瑞金融集團在 12 月 9 日的研究報告中將 Kodiak Sciences 的股票評級從 “持有” 上調至 “買入”，並設定了 $20.00 的目標價。</p>
</div><p><strong>Read Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 KOD 的最新股票報告</strong></p>
</div><h2>Kodiak Sciences Company Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc 是一家臨牀階段的生物製藥公司，研究、開發和商業化治療視網膜疾病的療法。其主要產品候選藥物是 tarcocimab tedromer（KSI-301），這是一種抗血管內皮生長因子抗體生物聚合物，目前正在進行治療濕性年齡相關性黃斑變性（AMD）的 IIb/III 期臨牀研究，以及用於治療糖尿病性黃斑水腫、因視網膜靜脈阻塞引起的初發性黃斑水腫和非增殖性糖尿病視網膜病變的 III 期臨牀研究。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>What is Short Interest? How to Use It</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Kodiak Sciences</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>便士股票激增 70%：買入的一個理由，賣出的五個理由</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>公用事業股票解析 – 如何以及為何投資公用事業</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KOD"/></p>
<h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Kodiak Sciences 嗎？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Kodiak Sciences 並不在名單上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kodiak Sciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kodiak Sciences（納斯達克股票代碼：KOD）公佈收益結果，每股收益超出預期 0.06 美元